StageZero Life Sciences Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

James Howard-Tripp

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.9yrs
Proprietà del CEO	0.2%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	16.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

James Howard-Tripp

7.9yrs

Mandato

US$270,000

Compensazione

Mr. James R. Howard-Tripp has been the Executive Chairman of StageZero Life Sciences Ltd. (formerly known as GeneNews Limited) (also known as ChondroGene Ltd.) since July 12, 2013 and has been its Chief Ex...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
James Howard-Tripp	Executive Chairman & CEO	22.5yrs	US$270.00k	0.19% € 6.3k
Rory Riggs	Independent Director	24.5yrs	US$40.00k	10.15% € 339.5k
Garth A. MacRae	Independent Director	24.2yrs	US$40.00k	0.12% € 4.0k
Lawrence Cohen	Member of Colorectal Cancer Clinical Advisory Board	15.7yrs	Nessun dato	Nessun dato
David Sidransky	Member of Colorectal Cancer Clinical Advisory Board	no data	Nessun dato	Nessun dato
Khursheed Jeejeebhoy	Member of Colorectal Cancer Clinical Advisory Board	15.7yrs	Nessun dato	Nessun dato
Harry Glorikian	Independent Director	16.2yrs	US$40.00k	0.087% € 2.9k
Richard Wender	Member of Colorectal Cancer Clinical Advisory Board	no data	Nessun dato	Nessun dato
Bernard Levin	Chairman of Colorectal Cancer Clinical Advisory Board	17yrs	Nessun dato	Nessun dato
David Lieberman	Member of Colorectal Cancer Clinical Advisory Board	no data	Nessun dato	Nessun dato
Barry Stein	Member of Colorectal Cancer Clinical Advisory Board	15.7yrs	Nessun dato	Nessun dato
Jeffrey Baker	Member of Colorectal Cancer Clinical Advisory Board	15.7yrs	Nessun dato	Nessun dato

16.2yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 61N1 è composto da personale esperto e esperto (durata media dell'incarico 16.2 anni).

StageZero Life Sciences Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Stagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COO

Insufficient new directors

StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022

StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021

Recent updates

StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)

StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings

Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)

StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)

Insufficient new directors

StageZero Life Sciences Ltd. to Report Q3, 2022 Results on Nov 15, 2022

StageZero Life Sciences Ltd. announced that it has received CAD 0.177 million in funding

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)

StageZero Life Sciences Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Stagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COO

First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)

StageZero Life Sciences Ltd. to Report Q1, 2022 Results on May 17, 2022

Insufficient new directors

StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)

StageZero Life Sciences Ltd. Launches AVRT Program for Patients Living in the United Kingdom

StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022

StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022

StageZero Life Sciences Ltd. announced that it has received CAD 1.87 million in funding

StageZero Life Sciences Ltd. announced that it expects to receive CAD 1.87 million in funding

StageZero Life Sciences Ltd. announced that it has received CAD 4.200001 million in funding

StageZero Life Sciences Ltd. announced that it expects to receive CAD 4.200001 million in funding

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)

StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp.

Interim Chief Financial Officer Carl Solomon has left the company

Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)

Stagezero Life Sciences Offers Drive-Up, COVID-19 PCR Travel Testing with Results Reported the Same Day

First quarter 2021 earnings released

Full year 2020 earnings released

StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021

New 90-day high: €0.90

New 90-day high: €0.60

New 90-day low: €0.39

StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million.

StageZero Life Sciences Ltd. to Report Q3, 2020 Results on Nov 18, 2020

StageZero Life Sciences Ltd. to Provide Rapid Testing Services for Travelers from U.S. and Canada

StageZero Life Sciences Ltd. Launches Saliva PCR Testing for the Detection of the SARS-COV-2 Virus

New 90-day high: €0.51

Earnings released

StageZero Life Sciences Ltd. to Report Q2, 2020 Results on Aug 14, 2020

StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million.

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media